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Under various conditions, mammals have the ability
to maintain serum glucose concentration within
a narrow range. SIRT1plays an important role in regu-
latinggluconeogenesis and fatmetabolism; however,
the underlying mechanisms remain elusive. Here, we
show that SIRT1 forms a complex with FOXO3a and
NRF1 on the SIRT6 promoter and positively regulates
expression of SIRT6, which, in turn, negatively regu-
latesglycolysis, triglyceride synthesis, and fatmetab-
olism by deacetylating histone H3 lysine 9 in the
promoter ofmany genes involved in these processes.
Liver-specific deletion of SIRT6 in mice causes
profound alterations in gene expression, leading to
increased glycolysis, triglyceride synthesis, reduced
b oxidation, and fatty liver formation. Human fatty
liver samples exhibited significantly lower levels of
SIRT6 than did normal controls. Thus, SIRT6 plays a
critical role in fatmetabolism andmay serve as a ther-
apeutic target for treating fatty liver disease, themost
common cause of liver dysfunction in humans.
INTRODUCTION
In budding yeast and Drosophila, the Sir2 histone deacetylase
acts as a chromatin silencer to regulate recombination, genomic
stability, and aging (Guarente and Kenyon, 2000). In mammals,
seven sirtuin proteins (SIRT1-7) have been found to share
homology with Sir2 and are suspected to have some functions
similar to those of Sir2 (Finkel et al., 2009;Mantel andBroxmeyer,
2008; Saunders and Verdin, 2007; Vaquero et al., 2007). These
proteins are primarily localized in different subcellular compart-
ments, with SIRT1 and SIRT2 both in the nucleus and the cyto-
plasm; SIRT3, SIRT4, and SIRT5 in the mitochondrion; and
SIRT6 and SIRT7 in the nucleus (Blander and Guarente, 2004;
Haigis and Guarente, 2006; Saunders and Verdin, 2007). Sirtuins
have emerged as broad regulators ofmany important processes,224 Cell Metabolism 12, 224–236, September 8, 2010 ª2010 Elsevieincluding cell fate determination, DNA damage repair, neuronal
protection, adaptation to calorie restriction (CR), organ metabo-
lism and function, age-related diseases, and tumorigenesis,
although much of the information has come from studies of
SIRT1 (Ahn et al., 2008; Deng, 2009; Finkel et al., 2009; Jacobs
et al., 2008; Kimet al., 2010; Saunders andVerdin, 2007; Vaquero
et al., 2007; Wang et al., 2008a; Wang et al., 2008b).
In response to fasting and CR, SIRT1 is induced, which then
interactswith anddeacetylatesperoxisomeproliferator–activated
receptor gamma-coactivator-1a (PGC-1a) and controls gluco-
neogenic and glycolytic pathways in the liver (Rodgers et al.,
2005;RodgersandPuigserver, 2007). For example, itwasdemon-
strated that SIRT1 and the histone acetyltransferase p300 form
a fasting-inducible switch that maintains energy balance and
regulates hepatic glucose production in mice through sequential
induction of CREB regulated transcription coactivator 2 (CRTC2)
and PGC-1a/FOXO1 (Liu et al., 2008). During early fasting, P300
modulates fasting gluconeogenesis through acetylating CRTC2,
which protects CRTC2 from ubiquitin-mediated degradation.
During late fasting, SIRT2 is induced, and the deacetylation of
CRTC2 by SIRT1 promotes ubiquitin-dependent degradation of
CRTC2, thereby attenuating the CRTC2-stimulated hepatic
glucose production. This switch strongly correlates with a transi-
tion fromahigh level of gluconeogenesis in the early phaseof fast-
ing toa lower level ofglucoseproductionat a later time.SIRT6may
also play a role in glucose metabolism, because SIRT6 null mice
suffer hypoglycemia before they die at 3–4 weeks of age (Mosto-
slavsky et al., 2006; Zhong et al., 2010). SIRT6 protein expression
can be induced by nutritional stress (Kanfi et al., 2008); however,
thephysiological roleofSIRT6 in response tonutritional statusand
its relationship with SIRT1 remains unclear.
To elucidate the function of SIRT6 and its relationship with
SIRT1, we performed an in vitro study to understand the regula-
tion of SIRT6 by SIRT1, generated liver-specific SIRT6 knockout
mice, and performed a comprehensive phenotypic analysis in
gene expression and acetylation associated with SIRT6 defi-
ciency. Our data revealed that SIRT1 regulates SIRT6 by forming
a complex with FOXO3a and NRF1 on the promoter of SIRT6. In
turn, SIRT6 deacetylates lysine 9 of histone H3 (H3K9) on the
promoters of many genes, which have an essential role in glycol-
ysis and lipid metabolism.r Inc.
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SIRT1 Positively Regulates SIRT6
We first investigated the relationship between SIRT1 and SIRT6
in mice under fed, fasted, and re-fed conditions. Analysis of
multiple organs revealed increased SIRT1 protein in the brain,
liver, white adipose tissue (WAT), and kidney of fasted mice to
a varying degree, although SIRT1 mRNA was increased in the
brain only (Figures 1A and 1C). In contrast, SIRT6 mRNA and
protein were coordinately increased in the brain, WAT, and liver
in fasted mice (Figures 1B and 1C). Next, we performed a time-
course study in the liver after fasting. We detected a positive
correlation of SIRT1 induction and SIRT6 induction, and in
addition, we found that the increase in SIRT1 protein occurred
earlier than that of SIRT6 (Figure 1D). For example, an obvious
increase in SIRT1 occurred at 12 hr and peaked at 18 hr after
fasting, whereas a significant increase in SIRT6 was detected
at 18 hr. Of note, fasting also induced expression of the gluco-
neogenic genes G6Pase and phosphoenolpyruvate carboxyki-
nase 1 (Pepck) (Figure 1E) and inhibited expression of glycolytic
genes glucokinase (Gk) and liver pyruvate kinase (Lpk)
(Figure 1F). A similar expression pattern of SIRT1 and SIRT6
induction was also detected in cultured primary hepatocytes
and hepatoma cell lines in the absence of glucose (see Figures
S1A–S1D available with this article online).
To further elucidate the relationship between SIRT1 and
SIRT6, we examined SIRT6 expression in the liver of Sirt1/
mice (Wang et al., 2008a). Our data revealed that both SIRT6
mRNA and protein were reduced by 50% and failed to be
induced by fasting (Figures 1G and 1H). Furthermore, SIRT1
ectopic expression in Hepa1-6 cells induced SIRT6 mRNA in
glucose-containing medium, which was further increased in
the absence of glucose (Figure 1I). Conversely, siRNA-mediated
SIRT1 knockdown blocked SIRT6 induction in the absence or
presence of glucose (Figure 1J), indicating that SIRT1 is involved
in maintaining SIRT6 expression under the physiological condi-
tions and is required for SIRT6 induction during fasting.
Regulation of SIRT6 by SIRT1 through NRF1-Binding
Sites in the SIRT6 Promoter
To understand the mechanism of SIRT6 induction by SIRT1, we
examined the activity of the SIRT6 promoter. Our data using
serial deletions of the SIRT6 promoter revealed that a region
between 0.17 kb and 0.13 kb was essential for the stimulatory
effect by glucose starvation (Figure S2A). Using a software
program for candidate transcription factors, we identified two
predicted nuclear respiratory factor 1 (NRF1)–binding sites in
this region (Figure S2B). Mutation of either site significantly
impaired SIRT6 induction in the absence of glucose, whereas
mutation of both sites completely blocked the induction
(Figure 2A). These data indicate that NRF1-binding sites are
involved in the regulation of the SIRT6 promoter by glucose star-
vation.
NRF1 is a transcription factor, and its expression is regulated
by CR (Mahishi and Usdin, 2006; Nisoli et al., 2005). To under-
stand the role of NRF1 in the regulation of SIRT6 expression,
we performed both NRF1 overexpression and knockdown
experiments. Our data indicate that ectopic expression of
NRF1 did not have a significant effect on a SIRT6 promoterCell Mereporter (Figure 2B), whereas RNAi-mediated knockdown of
NRF1 blocked the induction of the SIRT6 promoter by glucose
starvation (Figure 2C). A similar effect was observed for endog-
enous SIRT6 mRNA expression (Figures S2C and S2D). The
amount of endogenous NRF1 is sufficient to maintain SIRT6
expression either with or without glucose; thus, an increase in
NRF1 by ectopic expression does not have additional effects.
Next, we showed that ectopic expression of SIRT1 increased
SIRT6 promoter activity by approximately three-fold, either with
or without glucose, and this stimulatory effect was lost when the
NRF1-binding sites in the SIRT6 promoter were mutated
(Figure 2D). Furthermore, SIRT6 promoter activity induced by
the absence of glucose could be blocked by RNAi-mediated
knockdown of SIRT1 (Figure 2E). These data suggest that
SIRT1 plays an important role in regulating SIRT6 through
NRF1-binding sites in the SIRT6 promoter.
Regulation of SIRT6 by SIRT1, FOXO3a, and NRF1
Protein Complex upon Nutritional Stress
FOXO3a plays an important role in SIRT1 induction by glucose
and serum starvation (Nemoto et al., 2004). Therefore, we deter-
mined whether FOXO3a is also involved in the regulation of
SIRT6 expression. We found that SIRT6 promoter activity was
increased four-fold after transfection of a FOXO3a expression
vector, compared with a GFP expression vector in the presence
of glucose, and that the induction was increased further in the
absence of glucose (Figure 2F). Conversely, knockdown of
FOXO3a by siRNA significantly reduced SIRT6 promoter activity
(Figure 2G). Our analysis of endogenous SIRT6 mRNA
(Figure 2H) expression in Hepa1-6 cells confirmed these
changes. Thus, both SIRT1 and FOXO3a were capable of regu-
lating the expression of SIRT6 mRNA through the NRF1-binding
sites in both fed and fasting conditions.
Next, we studied potential interactions among SIRT1,
FOXO3a, and NRF1 in regulating SIRT6 expression. We showed
that cotransfection of SIRT1 and FOXO3a enhanced SIRT6
expression, compared with transfection of these genes alone,
as revealed by a SIRT6 promoter reporter assay (Figures S3A
and S3C) and endogenous SIRT6 gene expression (Figures
S3B and S3C) either with or without glucose. We found that,
although ectopic overexpression of NRF1 did not have an
apparent effect on SIRT6 induction by SIRT1 and/or FOXO3a
(data not shown), siRNA-mediatedNRF1 knockdown completely
blocked such induction (Figure 3A). This finding suggests that
the amount of endogenous NRF1 is sufficient for SIRT6 induction
by SIRT1 and/or FOXO3a. In addition, FOXO3a knockdown
blocked induction of SIRT6 by SIRT1 (Figure S3D) and the
absence of SIRT1 blocked induction of SIRT6 by FOXO3a
(Figure S3E). Collectively, these data suggest that SIRT1,
FOXO3a, and NRF1 might form a complex on the SIRT6
promoter with a defined configuration.
In light of these findings, we examined whether these factors
could bind to the SIRT6 promoter using chromatin immunopre-
cipitation (ChIP) assay.We showed that both SIRT1 and FOXO3a
bind to a fragment containing NRF1 sites on the SIRT6 promoter.
This binding was enhanced by approximately three-fold in the
absence of glucose, whereas the binding of NRF1 was not
affected (Figure 3B). Using an oligonucleotide pull-down assay,
it was determined that the NRF1-binding sites were critical fortabolism 12, 224–236, September 8, 2010 ª2010 Elsevier Inc. 225
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Figure 2. Regulation of SIRT6 by SIRT1, FOXO3a, and NRF1
(A) Absence of glucose in Hepa1-6 cells induced luciferase activity of a SIRT6 promoter reporter, whereasmutation of NRF1-binding sites abolished the induction.
(B and C) Effect of NRF1 ectopic expression (B) and RNAi-mediated knockdown (C) on a SIRT6 promoter reporter.
(D and E) Ectopic expression of SIRT1 increased SIRT6 promoter activity in the presence or absence of glucose (D), whereas mutation of NRF1-binding sites (D),
or RNAi-mediated knockdown of SIRT1 (E) abolished the induction.
(F and G) Ectopic expression of FOXO3a increased SIRT6 promoter activity in the presence or absence of glucose (F), whereas RNAi-mediated knockdown of
FOXO3a inhibits it (G).
(H and I) Absence of glucose induces expression of SIRT6 mRNA, which is further increased by overexpression of FOXO3a (H), whereas RNAi-mediated knock-
down of FOXO3a abolished the induction (I).
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mediated knockdown of either FOXO3a or SIRT1 (Figures S3G
and S3H) blocked interaction of these factors at the NRF1 sites,
whereas knockdown of either of them did not affect the binding
of NRF1 to the SIRT6 promoter (bottom lane of Figures S3G and
S3H). These data suggest that both SIRT1 and FOXO3a bindFigure 1. Regulation of SIRT1 and SIRT6 Expression by Nutrient Depri
(A–C) Levels of mRNA (A and B) and protein (C) of SIRT1 and SIRT6 in multiple o
(D–F) Levels of SIRT1 and SIRT6 protein (D), G6Pase and PEPCK mRNA (E), an
fasting.
(G and H) Levels of SIRT6 mRNA revealed by Real-Time RT-PCR (G) and protein
(I and J) Overexpression of SIRT1 increased endogenous SIRT6 in the presenc
blocked SIRT6 induction in the absence of glucose (J) revealed by real-time PCR
Cell Mecooperatively to the SIRT6 promoter, whereas binding of NRF1
to the SIRT6 promoter does not require SIRT1 or FOXO3a.
Next, we performed experiments to examine protein-protein
interaction. We showed that all three proteins (SIRT1, FOXO3a,
and NRF1) interacted with each other in cells in the presence
of glucose, whereas the interaction was markedly enhanced invation
rgans of mice under fed ad libitum (AL), starved (S), or re-fed for 24 hr.
d GK and LPK mRNA (F) in the liver of wild-type mice during a time course of
(H) in the liver from wild-type and Sirt1/ mice.
e and absence of glucose (I), whereas RNAi-mediated knockdown of SIRT1
. * p < 0.05, by Student’s t test in all figures.
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Figure 3. SIRT1, FOXO3a, and NRF1 Form a Protein Complex on the NRF1-Binding Sites of the SIRT6 Promoter
(A) Expression of SIRT1 and FOXO3a synergistically activated a SIRT6 promoter reporter, which is blocked by siRNA specific to NRF1.
(B) Binding of NRF1, SIRT1, and FOXO3a to the SIRT6 promoter in the presence or absence of glucose, as revealed by ChIP assay.
(C) Interaction of FOXO3a, SIRT1, and NRF1 in cultured cells in either the presence or absence of glucose, as revealed by immunoprecipitation (IP).
(D) Pull-down of 35S-FOXO3a, but not 35S-SIRT1, by GST tagged-NRF1.
(E) SIRT1 pulls down both FOXO3a and NRF1 in Hepa1-6 cells. However, SIRT1 could not pull down NRF1 in Hepa1-6 cells carrying a stably transfected shRNA
for FOXO3a (SS3-16).
(F) Wild-type SIRT1 deacetylates FOXO3a, which is enhanced in the absence of glucose in Hepa1-6 cells, and the deacetylated form of FOXO3a interacts more
abundantly with NRF1.
Cell Metabolism
SIRT6 Deficiency Results in Fatty Liver Formationthe absence of glucose (Figure 3C). Thus, glucose deprivation
enhanced the formation of a SIRT1-FOXO3a-NRF1 (SFN) protein
complex on the SIRT6 promoter that is responsible for the228 Cell Metabolism 12, 224–236, September 8, 2010 ª2010 Elsevieinduction of SIRT6 expression. Notably, our study revealed
that GST-tagged NRF1 only pulled down 35S-FOXO3a but
not 35S-SIRT1 (Figure 3D). Furthermore, shRNA-mediatedr Inc.
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between SIRT1 and NRF1 (Figure 3E). Altogether, these data
indicate that NRF1 binds directly to the SIRT6 promoter irrespec-
tive of glucose concentration, whereas SIRT1 binds to NRF1
through FOXO3a.
Previous studies have shown that SIRT1 binds and deacety-
lates FOXO3a (Brunet et al., 2004; Motta et al., 2004). Because
we found that expression of a dominant-negative mutant form
of SIRT1—SIRT1 (HY), which lacks deacetylase activity—
blocked the induction of SIRT6 by SIRT1 and/or FOXO3a
(Figures S3A–S3C), we investigated whether the acetylation
status of FOXO3a could affect its interaction with NRF1. Our
data showed that the presence of wild-type SIRT1 repressed
FOXO3a acetylation as compared with expression of the mutant
SIRT1 (HY) (Figure 3F). The absence of glucose further
decreased FOXO3a acetylation (compare the first 2 lanes in
Figure 3F), whereas no reduction of FOXO3a acetylation was
observed in the SIRT1 (HY) transfected cells (compare the last
2 lanes in Figure 3F). The data also revealed increased interac-
tion between FOXO3a with NRF1 in the cells with expression
of wild-type SIRT1, compared with cells with mutant SIRT1
(Figure 3F). A stronger band was also detected in the wild-type
SIRT1-expressed cells in the absence of glucose (Figure 3F).
Altogether, these data indicate that the absence of glucose
enhances the interaction between SIRT1 and FOXO3a, as well
as the deacetylation of FOXO3a. Deacetylated FOXO3a has
higher binding affinity for NRF1, resulting in the increased quan-
tity of SFN complex on the SIRT6 promoter that accounts for the
increased expression of SIRT6 upon nutritional stress.
Liver-Specific Knockout of SIRT6 Results in Fatty Liver
The observation that up-regulation of SIRT6 through the SFN
complex under fasting conditions suggests that SIRT6 plays
a role in glucose metabolism in the liver. Because Sirt6/
mice die shortly after weaning (Mostoslavsky et al., 2006), we
generated liver-specific SIRT6 knockout mouse using albumin-
Cre (Yakar et al., 1999) to overcome this early postnatal lethality
(Figure S4). Sirt6Co/Co;Alb-Cre mice appeared morphologically
normal and displayed comparable levels of blood glucose at
one month of age (data not shown), suggesting that the hypogly-
cemia and lethal phenotype observed in Sirt6/ mice
(Mostoslavsky et al., 2006) are not caused by the lack of
SIRT6 in the liver. Consistent with this observation, our study
using older mice ranging in age from 1 to 8 months also failed
to reveal a significant difference in blood glucose between
SIRT6 mutant and control mice after feeding (data not
shown). Of note, our analysis of older Sirt6Co/Co;Alb-Cre mice
(R8 months of age) revealed slightly increased blood glucose
(Figure 4A). The mutant mice also exhibited slightly higher levels
of glucose in the glucose tolerance test (GTT) (Figure 4B) and
insulin tolerance test (ITT) (Figure 4C), although glucose level
did not reach a significant level atmost time points. The elevation
in glucose might be caused by an increase in hepatic glucose
production. However, additional studies on hepatic gluconeo-
genesis, including the pyruvate tolerance test and clamp anal-
ysis, failed to detect increased hepatic gluconeogenesis in these
mutant mice (data not shown), suggesting that this phenotype
might not be a direct consequence of SIRT6 deficiency in the
liver.Cell MeSirt6Co/Co;Alb-Cre mice gradually increased in body weight
beginning at 5 months of age, although such an increase did
not reach a statistically significant level (Figure 4D). There was
no significant difference in body fat, plasma concentration of
lipids and insulin, as well as insulin signaling between SIRT6
mutant and wild-type mice (data not shown). However, our
examination revealed that 43% (3/7) of Sirt6Co/Co;Alb-Cre mice
started to develop fatty liver at 5–6 months of age, and reached
90% (9/10) from 7.5–13 months of age, as revealed by increased
liver weight (Figure 4E), hepatic triglyceride (TG) (Figure 4F),
gross morphology (Figures 4G and 4H), histopathology (Figures
4I and 4J), and Oil Red O staining (Figures 4K and 4L).
In contrast, only 12% (2/17) of control animals exhibited mild
fatty liver from 5–13 months of age.
Theoretically, an increase in hepatic TG could be caused by
reduced VLDL export, increased TG synthesis, and/or increased
TG uptake. Our experiments indicated that SIRT6 mutant mice
had a slightly higher rate of TG secretion from the liver to the
blood compared with wild-type mice (Figure 4M). To measure
TG synthesis, we cultured primary hepatocytes in the presence
of oleic acid, which stimulates TG synthesis, with or without
3H-Palmitate. The data revealed significantly higher levels of
TG in the mutant cells than controls in both conditions (Figures
4N and 4O). These data suggest that the increased hepatic TG
in SIRT6mutant micemay be caused by increased TG synthesis,
rather than reduced TG secretion.
SIRT6 Deficiency Causes Altered Expression of Genes
Involved in Glycolysis and Lipid Metabolism
Fatty liver occurs at a high frequency in humans and may be
caused by altered signaling in multiple biological pathways,
including glycolysis, fatty acid uptake and synthesis, and TG
synthesis (Postic and Girard, 2008). We observed an inverse
correlation in gene expression between SIRT6 and glycolytic
genes, GK and LPK (Figures 1D and 1F) during the course of
fasting, so we first investigated the impact of SIRT6 deficiency
on glycolysis. Our analysis of the fatty liver of 8–9-month old
mutant mice revealed significantly increased expression of
both Gk and Lpk (Figure 5A). To investigate whether this change
in gene expression is directly related to a SIRT6 deficiency, we
analyzed the liver of mutant mice at 2–3 months of age prior to
fatty liver development. We found that SIRT6 deficiency resulted
in approximately a two-fold increase in Gk mRNA, compared
with wild-type mice (Figure 5B). Upon fasting, Gk mRNA level
was reduced to 20% of the fed level in wild-type mice; however,
in SIRT6 mutant mice, this reduction was significantly attenu-
ated, leading to about six-fold higher Gk mRNA (Figure 5B).
Significantly higher levels of GK protein (Figure 5C) and
enzymatic activity (Figure 5D) were observed in the SIRT6
mutant liver than control liver in both fed and fasting conditions.
A similar increase in LpkmRNA was also observed in the liver of
Sirt6Co/Co;Alb-Cre mutants, compared with wild-type mice
(Figure 5B). These data indicate that SIRT6 deficiency increases
glycolysis under both fed and fasting conditions.
Next, we checked the expression level of lipid metabolism–
related genes. The liver of 2–3-month-old Sirt6Co/Co;Alb-Cre
mice exhibited moderate, yet statistically significant, increased
levels of fatty acid translocase (Fat), which uptakes long chain
fatty acid from blood, compared with the control mice in bothtabolism 12, 224–236, September 8, 2010 ª2010 Elsevier Inc. 229
Figure 4. Phenotypic Analysis of Mice Carrying a Liver-Specific Knockout of SIRT6
(A) Blood glucose level (mg/dL) of 8–9-month-old SIRT6 MT and WT mice under fed or 24 hr fasting condition.
(B) Glucose tolerance test. Mutant mice had a slightly higher, but not significantly different glucose levels at 15 and 30 min than wild-type mice.
(C) Insulin tolerance test expressed as percentage of basal glucose level. We have also measured glucose value in the area under the curve (AUC) for both GTT
and ITT, and no difference was found between wild-type and mutant mice.
(D) Body weight (grams) of SIRT6 mice at 2 months (WT, 17; and MT, 15), at 5–6 months (WT, 18; and MT, 15), and at 8–10 months (WT, 15; and MT, 22).
(E and F) Percentage of liver weight/body weight (E) and hepatic TG levels (F) of 8–9-month-old SIRT6 MT and WT mice.
(G–L) Morphology (G and H), H&E sections (I and J) and Oil Red O staining (K and L) of livers from MT (G, I, and K) and WT (H, J, and L) mice. Bar in (G and H) is
1 cm. At least 6 pairs of mice were analyzed in each experiment.
(M) TG secretion rate to plasma (mg/hour/gram of liver).
(N and O) TG content in primary hepatocytes measured by 3H-palmitate incorporation (N) and TG level (O) at different times. In panel (O), TG production increases
1.54 fold in wild-type cells and 2.45 fold in mutant cells from 0 hr to 12 hr, respectively. This increase is statistically significant with p < 0.04.
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Figure 5. SIRT6 Regulates the Expression of Genes Related to Glycolysis and Lipid Metabolism
(A and B) mRNA levels of GK and LPK in the liver of WT and MT mice at 8–9 months (A) and at 2–3 months (B) under fed ad libitum (AL) or 24 hr starvation (S)
detected by using real-time RT-PCR.
(C) Protein expression of genes involved in glycolysis and lipid metabolism.
(D) GK enzymatic activity in the liver of WT and MT mice.
(E–G)mRNA levels of FAT and FATP (E and F) and several genes involved in TG synthesis in the liver (G). Mice used in panels (F andG) were 8–9months old, and in
panels (C–E) were 2–3 months old. At least 5 pairs of mice were used for each experiment.
(H) De novo lipogenesis activity in the primary hepatocytes under fed or fasted condition.
(I and J) Absence of SIRT6 decreased the expression levels of genes involved in b oxidation revealed by real-time RT-PCR (I) and fatty acid b oxidation revealed by
enzymatic activity (J).
(K) Gene expression in primary hepatocytes upon acute knockdown of SIRT6 for 36 hr revealed by real-time PCR. Abbreviations for genes that are not mentioned
in the text: ACC1, acetyl-CoA carboxylase-1; Elovl6, long-chain elongase; FAS, fatty acid synthase; GPAT, mitochondrial glycerol 3-phosphate acyltransferase;
and SCD1, stearoyl-CoA desaturase-1.
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SIRT6 Deficiency Results in Fatty Liver Formationfed and fasting conditions (Figures 5C and 5E). Fat transcripts
increased about three-fold in 8–9-month-old mutant mice,
compared with controls (Figure 5F). Sirt6Co/Co;Alb-Cre mice
also exhibited increased mRNA of fatty acid transport
protein (Fatp) (Figure 5F) and of several genes involved in lipo-
genesis, fatty acid elongation, and desaturation (Figures 5C
and 5G). Consistent with the increased expression of lipogenic
genes, about a three-fold increase in lipid production was de-
tected in the primary hepatocytes of Sirt6Co/Co;Alb-Cre mice
than that of WT mice under both fed and fasting conditions
(Figure 5H). SIRT6 mutant liver also exhibited significantly
decreased levels of liver–carnitine palmitoyltransferase I
(L-cpt1) and acyl-Coenzyme A oxidase 1, palmitoyl (Aox)
(Figures 5C and 5I), and lower levels of fatty acid b oxidation
(Figure 5J), whereas expression of genes upstream of TG
synthesis or involved in TG secretion were not affected (data
not shown).
These data suggest that SIRT6 may regulate expression of
many genes involved in various steps of glycolysis and lipid
metabolism. To rule out a possibility that the expression change
of these genes is secondary to a long-term loss of SIRT6, we
performed acute knockdown of SIRT6 in primary hepatocytes.
Our data showed that SIRT6 knockdown caused an increased
expression of these genes (Figure 5K). Conversely, infection of
a SIRT6 expression vector using a lentiviral system into these
cells resulted in a significant reduction in expression of these
genes than the control vector under fed and fasting conditions
(Figure S5A). These data provide convincing evidence that
SIRT6 inhibits the expression of these genes.
SIRT6 Binds and Deacetylates H3K9 in the Promoters
of Genes Involved in Glycolysis and Lipid Metabolism
First, we investigated the mechanism underlying expression
changes of these genes that are associated with SIRT6 defi-
ciency. We found that levels of acetylated H3K9 (AcH3K9)
were significantly higher in the liver of SIRT6 mutant mice than
controls (Figure 6A). Furthermore, fasting significantly reduced
AcH3K9 in the liver of wild-type mice, but SIRT6 deficiency
blocked such a reduction. A similar pattern of AcH3K9 levels
was observed in SIRT6 mutant mouse embryonic fibroblast cells
(MEFs), whereas modification of several other lysines in H3, and
K16 of H4 was not affected (data not shown). Furthermore,
primary hepatocytes that overexpressed FLAG-SIRT6 exhibited
reduced levels of AcH3K9 (Figure 6B). These data suggest that
SIRT6 plays a specific role in deacetylation of AcH3K9 in both
fed and fasting conditions.
Next, we investigated whether altered AcH3K9 could be
detected in the promoter of the genes that were studied earlier.
ChIP assay of the proximal region revealed increased levels of
AcH3K9 in the promoters of Gk, Lpk, Fat, ACC1, FAS, Elovl6,
and SCD1 in the liver of SIRT6 mutant mice (Figures 6C–6G).
There was no obvious change in the promoters of GPAT and
DGAT, which is consistent with their expression (Figure S5B).
To confirm whether SIRT6 can recruit and deacetylate H3K9
on these promoters, we performed ChIP assay after infection
of a FLAG-SIRT6 vector into primary hepatocytes that were
cultured under fed and fasted condition. SIRT6-infected cells
had a lower level of AcH3K9 in the proximal promoter region of
these genes than cells infected with vector control, but no differ-232 Cell Metabolism 12, 224–236, September 8, 2010 ª2010 Elsevieence was found in the coding or intron region of those genes
(Figure S5C). We further investigated whether SIRT6 could
bind to the promoter of these genes. ChIP analysis showed
that SIRT6 was recruited to the proximal region but not to the
coding/intron region of those genes (Figure S5D, and data not
shown). Furthermore, ChIP analysis on endogenous genes also
indicated that SIRT6 occupies the promoters of these genes
(Figure 6H).
In addition, we analyzed the changes in gene expression inWT
and SIRT6 mutant livers at both 2 and 8 months of age by micro-
array analysis and observed that expression of many genes
involved in lipid and carbohydrate metabolism were altered
Table S1 and GSE21965. The gene change involved in lipid
metabolism was consistent with mRNA changes we detected
by real-time RT PCR.
Finally, we reintroduced SIRT6 to the liver using a lentiviral-
mediated approach. The expression of SIRT6 in SIRT6 mutant
liver significantly reversed increased levels of AcH3K9 (Figure 6I)
and increased gene expression (Figure 6J), yielding strong
evidence that the increased AcH3K9 and altered gene expres-
sion is a direct consequence of SIRT6 mutation. Of note, this
short-term SIRT6 expression did not have an obvious effect on
the fatty liver phenotype, whichmay reflect a view that the forma-
tion of fatty liver is a long process in the SIRT6 mutant liver. Alto-
gether, these data indicate that SIRT6 binds and deacetylates
AcH3K9 in the promoter of many genes that are involved in
glucose and lipid metabolism, and SIRT6 deficiency resulted in
altered expression of these genes, which ultimately led to fatty
liver in the mutant mice.
Reduced Expression of SIRT1 and SIRT6 in Human Fatty
Liver Samples
It has been shown that hepatocyte-specific deletion of SIRT1
resulted in fatty liver in mice (Purushotham et al., 2009) and that
expression of SIRT1 was reduced in nonalcoholic fatty liver
induced by high-fat diet in rats (Deng et al., 2007). These findings
prompted us to examine expression of SIRT1 and SIRT6 in
human fatty liver. Our data revealed a significant reduction of
both SIRT1 and SIRT6 in human fatty liver samples, compared
with normal controls (Figure 7A). The fatty livers also exhibited
significantly increased mRNA of GK and LPK (Figure 7B). These
data, combined with findings that SIRT1 regulates SIRT6
and that liver-specific deletion of SIRT6 inmice causes fatty liver,
implicate an inhibitory role of SIRT6 in human fatty liver formation.
DISCUSSION
In this study, we showed that nutrient deprivation induces
expression of both SIRT1 andSIRT6. Although it has been shown
that nutritional stress induces SIRT1 through p53 and FOXO3a
(Nemoto et al., 2004), our data indicate that the induction of
SIRT6 requires SIRT1, because the absence of SIRT1 blocked
SIRT6 induction. In addition, we showed that, upon nutritional
stress, SIRT1 deacetylates FOXO3a, which subsequently
enhances the formation of a SIRT1/FOXO3a/NRF1 (SFN) protein
complex on thepromoter of SIRT6 that positively regulatesSIRT6
expression. Thus, our study reveals for the first time, toour knowl-
edge, that SIRT1 regulates another sirtuin familymember through
interaction with other transcription factors.r Inc.
Figure 6. SIRT6 Is Recruited to and Deacetylates H3K9 in the Promoter of Many Genes
(A) Western blot analysis of nuclear extracts prepared from the liver of WT and MT mice under fed (AL) or 24 hr starvation (S).
(B)Western blot analysis of nuclear extracts prepared fromprimary hepatoctyes infected with pCDH-FLAG-SIRT6 or vector control under fed or fasting condition.
(C–G) ChIP analysis showing the acetylation pattern of H3K9 (C–G) in the promoter of several genes in samples extracted from the liver of WT andMTmice. Four
fragments (two in promoter region and two in exon/intron) for each gene were analyzed, and, in all cases, the absence of SIRT6 increased acetylation in the
promoter, but not in the exon/intron region (some data not shown).
(H) ChIP analysis showing the binding of SIRT6 to the promoter of several genes in samples extracted from the liver of WT and MT mice.
(I and J) Expression of Flag-tagged SIRT6 in SIRT6 mutant liver mediated by injection of lentivirus carrying Flag-tagged SIRT6 significantly reversed increased
levels of AcH3K9 (I) and gene expression (J). At least three pairs of SIRT6 mutant and control mice were used for each experiment.
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Figure 7. Reduced Levels of SIRT1 and
SIRT6 and Increased Levels of GK and LPK
in Human Fatty Liver Samples
(A) Western blot analysis of protein levels of SIRT1
and SIRT6 in fatty liver samples. Quantification of
gel intensity of eight normal livers and eight nonal-
coholic fatty livers was shown in right.
(B) mRNA levels of GK and LPK are revealed by
real-time RT-PCR in these samples. The fatty
livers and controls were provided by the Liver
Tissues Procurement and Distribution System
(University of Minnesota).
(C) An integratedmodel for functions of SIRT6 in in-
hibiting fatty liver formation through regulation of
glycolysis and lipid metabolism. SIRT6 deficiency,
consequently, results in fatty liver formation.
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SIRT6 Deficiency Results in Fatty Liver FormationAfter bypassing the early postweaning lethality associated
with SIRT6 deficiency (Mostoslavsky et al., 2006) using
a Cre-loxP-mediated liver specific knockout, we demonstrated
that SIRT6 negatively regulates the glycolytic genes, Gk and
Lpk, under both fed and fasting conditions. A previous study indi-
cated that SIRT1 interacts with and deacetylates PGC-1a and
controls gluconeogenic and glycolytic pathways in the liver
(Rodgers et al., 2005). Our data indicate that the absence of
SIRT6 does not affect expression of Pgc1a and its downstream
gene Pepck. It also did not affect blood glucose level under fed
condition, although a small, yet statistically significant, increase
in fasting glucose was observed in Sirt6Co/Co;Alb-Cre mice
8 months old and older. Thus, SIRT6 mediates a part of SIRT1
function and plays an essential role in glycolysis. In the SIRT6
liver-specific mutant mice, increased glycolysis eventually
affected the health of mutant mice as the result of an imbalance
in glucose metabolism.
An important finding is that the absence of SIRT6 results in
accumulation of TG, which is associated with fatty liver (den
Boer et al., 2004; Postic and Girard, 2008). Our data demon-
strated that SIRT6 deficiency resulted in increased expression
of genes responsible for hepatic long-chain fatty acid uptake
and reduced expression of genes for b oxidation. SIRT6 defi-
ciency also increased expression of several genes involved in
multiple steps of TG synthesis, whereas expression of genes
upstream of TG synthesis and TG secretion were not affected.
Increased TG synthesis was also observed in SIRT6 mutant
primary hepatocytes, compared with WT hepatocytes, when
cultured in vitro. Thesedata suggest that SIRT6 serves as a nega-
tive regulator of TG synthesis. Thus, the combined effect of
SIRT6 deficiency in the liver causes increased glycolysis,
elevated uptake of long chain fatty acid, reduced fat acid b oxida-
tion, and increased TG synthesis and lipogenesis, eventually
leading to fatty liver formation (Figure 7C).
It was reported that SIRT6modulates telomeric chromatin and
expression of downstream genes in the NF-kB signaling234 Cell Metabolism 12, 224–236, September 8, 2010 ª2010 Elsevier Inc.pathway through its H3K9 deacetylase
activity (Kawahara et al., 2009; Michishita
et al., 2008). Two recent studies also
found that SIRT6 deacetylates H3K56 at
telomeres and at global DNA levels inresponse to cell-cycle arrest, suggesting a possible mechanism
by which SIRT6 promotes genomic stability (Michishita et al.,
2009; Yang et al., 2009). Combined with the early postweaning
lethality associated with SIRT6 deficiency, these data under-
score important functions of SIRT6 in many biological
processes, including DNA damage repair, telomeric chromatin
integrity, glucose uptake, and aging through its deacetylase
activity and/or ADP-ribosyltransferase activity (Liszt et al.,
2005; Lombard et al., 2008;Michishita et al., 2008; Mostoslavsky
et al., 2006; Zhong et al., 2010). In this study, although we tried to
dissect the complexity of SIRT6 function by specifically deleting
SIRT6 in the liver and studying its effects on deacetylation of
H3K9 in the promoters of many genes that play a role in glycol-
ysis and lipid metabolism, it is possible that the absence of
SIRT6 could still have some effects on many other processes,
as revealed by earlier studies. For example, our analysis
confirmed that SIRT6 deacetylates H3K56 in DNA isolated
from the liver at the global level, but the biological relevance of
this modification in metabolism is not clear and will be an inter-
esting topic for future investigation. In addition, our microarray
analysis of the liver revealed altered expression of many genes
involved in multiple biological processes (Table S1). Although
many of the changes can be secondary, some others may be
directly linked to SIRT6 mutation, and their impact on histopath-
ological onset and development should be carefully investigated
in future studies.
The findings delineated herein have important clinical signifi-
cance because fatty liver disease is the most common cause
of liver dysfunction worldwide (Ahmed and Byrne, 2009; Rogers
et al., 2008). We found that human fatty livers exhibited lower
levels of SIRT6, compared with normal controls. In light of this
finding, SIRT6mutant and control mice could be used as amodel
in chemical screens for SIRT6 activators and TG synthesis
inhibitors, which may be beneficial for the prevention and/or
therapeutic treatment of fatty liver in affected individuals in the
near future.
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Mating and Genotyping Mice
Chimeric mice were mated with NIH Black Swiss females (Taconic) to screen
for germline transformation. Male mice bearing germline transmission were
mated with female FVB EII-Cre mice (Lakso et al., 1996) to generate condi-
tional SIRT6 mice, according to a procedure described elsewhere (Xu et al.,
2001). Mice carrying a SIRT6 conditional allele were genotyped by PCR using
primers P1 (50 GCTAATGGGAACGAGACCAA 30) and P2 (50 ACCCAC
CTCTCTCCCCTAAA 30). This primer pair flanks the LoxP insertion site in intron
1 and amplifies a 390-bp fragment from the wild-type Sirt6 gene and 444 bp
from the conditional allele. The recombination allele of SIRT6 is amplified using
primers P1 and P3 (50-GCGTCCACTTCTCTTTCCTG-30), which produces
a fragment of 524 bp. All experiments were approved by the Animal Care
and Use Committee of the National Institute of Diabetes, Digestive and Kidney
Diseases (ACUC, NIDDK).
Lentivirus Injection into Mouse Tail Vein
To prepare lentiviral particles for injection, 293 T cells were transfected with
PsPAX2, VSV-G, and either pCDH or pCDH-mSIRT6 Flag. After 2 days,
30 ml of virus-containing media was collected and concentrated by ultracen-
trifugation. Mice were then injected twice (once per week) by tail-vein injection
with 100 ml of concentrated virus. Mouse liver was then harvested for analysis
after 2 weeks.
Determination of Hepatic Triglyceride Secretion
We used a protocol modified from Tietge et al. (1999). Briefly, mice were in-
jected with 100 ml of 10% Tyloxapol (Triton WR1339, which inhibits all lipopro-
tein lipases and therefore clearance of TG from the blood) per animal by
IV injection, and blood was collected to check TG at 0 min, 1 hr, and 2 hr.
Plasma was separated and assayed for triglycerides. TG secretion rates
were expressed as milligram per kilogram per hr after normalizing with their
liver weight.
Triglyceride Assay in the Liver and Cultured Hepatocytes
The triglyceride level of liver was measured as described elsewhere (Jeong
et al., 2008; You et al., 2004). Liver extracts were prepared by homogenization
in 0.25% sucrose with 1 mmol/L EDTA, and lipids were extracted using
chloroform/methanol (2:1 v/v) and suspended with 5% fatty acid-free BSA.
Triglyceride level was measured using triglyceride assay reagents (Sigma
Chemical Co.). For measuring triglyceride synthesis in cultured primary hepa-
tocytes, freshly isolated hepatocytes from 5-week-old WT and MT mice were
cultured for 24 hr with normal media (DMEMwith 10% FBS) in the presence or
absence of oleic acid (500 mM). Quantitative estimation of hepatic triglyceride
accumulation was performed by extraction of hepatic lipids from cell homog-
enates using chloroform/methanol (2:1) and enzymatic assay of triglyceride
mass using EnzyChrom Triglyceride assay kit (Bioassay Systems).
Glucokinase Assay
Glucokinase activity was determined by an enzyme-linked assay based on the
NADP+/NADPH ratio (Gonzali et al., 2001). The proteins extracted frommouse
liver were incubated in the buffer with 12 mMMgCl2, 6.5 mM ATP, 1 mM DTT,
0.9 mM NADP+, 1 IU/ml glucose-6-phosphate dehdrogenase (Sigma), 45 mM
glucose, and 32 mM sodium-HEPES buffer (pH 7.6) at 22C, and then the
absorbance was measured at 340 nm for several time points.
De Novo Lipogenesis Assay
Primary hepatocytes were cultured with 10% DMEMwith insulin (100 nM) and
dexamethasone (1 mM) overnight and then were incubated with 74 KBq/ml
(2-14C) sodium acetate (2.07 GBq/mmol; GE Healthcare Inc.) for 1 hr. The cells
were lysed with 1 N NaOH and were acidified (Harada et al., 2007). Then, the
lipids were extracted with petroleum ether, and radioactivity was measured by
liquid scintillation counter (Beckman Inc.).
Fatty Acid b Oxidation Activity
Fatty acid b oxidation activity was measured by the method of Shindo et al.
(1978), with some modifications. Briefly, 0.3 g of fresh livers were homoge-
nized in 1.2 ml of 0.25 M sucrose containing 1 mM EDTA in a Potter-ElvehjemCell Mehomogenizer using a tight-fitting teflon pestle. Approximately 500 mg of
homogenate (no centrifugation) was incubated with the assay medium in
0.2 ml of 150 mM potassium chloride, 10 mM HEPES (pH 7.2), 0.1 mM
EDTA, 1 mM potassium phosphate buffer (pH 7.2), 5 mM Tris malonate,
10 mM magnesium chloride, 1 mM carnitine, 0.15% bovine serum albumin,
5 mM ATP, and 50 mM C14-palmitic acid (5.0 3 104 cpm of radioactive
substrate). The reaction was run for 30 min at 25C and was stopped by the
addition of 0.2 ml of 0.6 N perchloric acid. The mixture was centrifuged at
2,0003 g for 10min, and the unmetabolized fatty acids were removed by three
extractions using 2 ml of n-hexane. Radioactive degradation products in the
water phase were counted. In some experiments, 2 mM potassium cyanide
was added to the incubation mixture to inhibit mitochondrial b oxidation
activity. Fatty acid b oxidation activity was expressed as nanomoles per
minute per gram of liver.
Human Liver Clinical Samples
All of these nonalcoholic fatty liver samples were collected from donor livers or
recipient livers during liver transplantation from the Liver Tissue Procurement
and Distribution System, University of Minnesota. These samples are case
647, 50 years old, female white, AST 13 U/L; case 753, 16 years old, male,
AST 43 U/L; case 801, 44 years old, female white, AST 46; case 935, 60 years
old, female, AST 30; case 970, 62 years old, female, AST 25; case 1075, 56
years old, male, AST 77; case 1098, 59 years old, female, AST 64; and case
1095, 61 years old, female, AST 59. Normal healthy liver samples were also
provided by the Liver Tissue Procurement and Distribution System, and
were collected from the part of donor livers that was not used for transplanta-
tion. All of samples were collected by quickly freezing in liquid nitrogen, and
diagnosed as nonalcoholic steatohepatitis by histology.
Statistic Analysis
Student t test is used for data analysis. Bars represent ±SD, and asterisks
represents p < 0.05 in all corresponding figures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
one table, and five figures and may be found with this article online at
doi:10.1016/j.cmet.2010.06.009.
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